Reply, Letter to the Editor – The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma

Katie E. Rollins(University of Nottingham), Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Ian Macdonald(University of Nottingham), Amir Awwad(University of Nottingham), Abigail Ackner(University of Nottingham), Nilanjana Tewari(National Institute for Health and Care Research), Kenneth C. H. Fearon(Edinburgh Royal Infirmary), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Clinical Nutrition
March 17, 2016
10.1016/j.clnu.2016.03.006
Cited by 2

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374